Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CRISPR Therapeutics AG    CRSP   CH0334081137

CRISPR THERAPEUTICS AG

(CRSP)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo CRISPR Therapeutics AG
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Number of employees : 304 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Clustered Regularly Interspaced Short Palindromic Repeats - Associated Protein 93.12100%289.59100% +9169.85%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
Switzerland & United States3.12100%289.59100% +9169.85%
Managers
NameAgeSinceTitle
Samarth Kulkarni402018Chief Executive Officer & Director
Rodger Novak512017Chairman & President
Lawrence Klein372020Chief Operating & Business Officer
Michael John Tomsicek53-CFO & Principal Accounting Officer
Tony W. Ho, Dr.532017Executive VP, Head-Research & Development
Stephen R. Kennedy62-Head-Technical Operations
Simeon J. George, Dr.422015Independent Non-Executive Director
Ali Behbahani, Dr.432015Independent Non-Executive Director
Bradley Bolzon592016Independent Non-Executive Director
Katherine A. High, Dr.672019Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,847,745 60,848,959 85.9% 195,316 0.3% 85.9%
Shareholders
NameEquities%
ARK Investment Management LLC 8,457,320 12.0%
Capital Research & Management Co. (International Investors) 7,519,803 10.6%
Nikko Asset Management Americas, Inc. 3,697,667 5.23%
Versant Venture Management LLC 3,324,499 4.71%
GlaxoSmithKline plc 3,220,627 4.56%
Bayer Aktiengesellschaft 2,954,775 4.18%
Vertex Pharmaceuticals Incorporated 2,690,470 3.81%
Capital Research & Management Co. (Global Investors) 1,931,930 2.73%
NEA Management Co. LLC 1,590,002 2.25%
T. Rowe Price Associates, Inc. (Investment Management) 1,375,327 1.95%
Company contact information
CRISPR Therapeutics AG
Baarerstrasse 14
Zug 6300

Phone : +41.41.561.32.77
Web : http://www.crisprtx.com
Sector Biotechnology & Medical Research - NEC